These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 8567393)
1. High positive rate of pS2 expression in forefront intraductal cancerous area in breast cancer. Yamakawa T; Morimoto T; Sasa M; Numoto S; Monden Y Jpn J Cancer Res; 1995 Nov; 86(11):1035-40. PubMed ID: 8567393 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical survey of pS2 expression in intraductal lesions associated with invasive ductal carcinoma of the breast. Inaji H; Koyama H; Motomura K; Noguchi S; Tsuji N; Wada A Int J Cancer; 1993 Dec; 55(6):883-6. PubMed ID: 8253523 [TBL] [Abstract][Full Text] [Related]
3. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast]. Sánchez Salmón A; Argibay S; Arias JI; Ruibal A Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785 [TBL] [Abstract][Full Text] [Related]
4. [Analysis of the cytosolic content of the pS2 protein in breast cancer]. Tamargo F; Vizoso F; Lamelas ML; Rodil A; Vérez P; Raigoso P; Mulero M; Vázquez J; Roiz C; Allende MT Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999 [TBL] [Abstract][Full Text] [Related]
5. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay]. Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. Luqmani YA; Campbell T; Soomro S; Shousha S; Rio MC; Coombes RC Br J Cancer; 1993 Apr; 67(4):749-53. PubMed ID: 8385977 [TBL] [Abstract][Full Text] [Related]
7. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation]. Ruibal A; Arias JI; Resino C; Lapeña G; Schneider J; Tejerina A Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070 [TBL] [Abstract][Full Text] [Related]
8. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of the estrogen regulated pS2 protein in mammary tumors. Pichon MF; Milgrom E Crit Rev Oncol Hematol; 1993 Aug; 15(1):13-21. PubMed ID: 8240704 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of estrogen receptor in invasive human breast cancer: correlation with heat shock proteins, pS2 and oncogene products. Takahashi S; Narimatsu E; Asanuma H; Okazaki M; Okazaki A; Hirata K; Mori M; Chiba T; Sato N; Kikuchi K Oncology; 1995; 52(5):371-5. PubMed ID: 7637953 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer. Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases. Soubeyran I; Wafflart J; Bonichon F; de Mascarel I; Trojani M; Durand M; Avril A; Coindre JM Breast Cancer Res Treat; 1995 May; 34(2):119-28. PubMed ID: 7647329 [TBL] [Abstract][Full Text] [Related]
13. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494 [TBL] [Abstract][Full Text] [Related]
14. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study]. Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545 [TBL] [Abstract][Full Text] [Related]
15. pS2 expression in infiltrating ductal carcinoma of the breast correlates with oestrogen receptor positivity but not with histological grade and lymph node status. Looi LM; Azura WW; Cheah PL; Ng MH Pathology; 2001 Aug; 33(3):283-6. PubMed ID: 11523925 [TBL] [Abstract][Full Text] [Related]
16. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Hurlimann J; Gebhard S; Gomez F Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242 [TBL] [Abstract][Full Text] [Related]
17. Expression of pS2 protein in breast cancer. Crombach G; Ingenhorst A; Göhring UJ; Scharl A; Neuhaus W; Möbus V; Schaeffer HJ Arch Gynecol Obstet; 1993; 253(4):183-92. PubMed ID: 8161252 [TBL] [Abstract][Full Text] [Related]
18. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778 [TBL] [Abstract][Full Text] [Related]
19. pS2 negativity in postmenopausal women with ER+PgR+ infiltrating ductal breast carcinoma is associated with reduced hormone dependence and increased proliferation and aneuploidy of the tumors. Ruibal A; Schneider J; del Rio C; Arias J; Núñez MJ; Piqueras V; Tejerina A Int J Biol Markers; 1999; 14(3):186-8. PubMed ID: 10569142 [No Abstract] [Full Text] [Related]
20. Expression of the pS2 protein and correlation with estrogen receptor status in fine-needle aspirates from breast carcinomas. Sauer T; Naess O Diagn Cytopathol; 1994; 11(2):165-7. PubMed ID: 7813365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]